$WGS
GeneDx Holdings Corp. Stock $wgs

$wgs Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000181833122000069 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$83.23M	$36.17M	$53.94M
YoY Change	92.77%	-23.07%	-15.98%
Cost Of Revenue	$69.69M	$65.77M	$48.32M
YoY Change	35.34%	36.51%	-29.49%
Gross Profit	$13.55M	-$29.60M	$5.625M
YoY Change	-263.06%	2442.78%	-230.12%
Gross Profit Margin	16.28%	-81.83%	10.43%
Selling, General & Admin	$89.31M	$104.2M	$72.33M
YoY Change	45.75%	231.23%	-47.36%
% of Gross Profit	659.19%		1285.88%
Research & Development	$13.35M	$27.17M	$21.32M
YoY Change	-25.11%	127.31%	-59.88%
% of Gross Profit	98.56%		378.93%
Depreciation & Amortization	$6.995M	$6.627M	$5.803M
YoY Change	27.39%	17.94%	18.38%
% of Gross Profit	51.63%		103.16%
Operating Expenses	$102.7M	$131.3M	$93.65M
YoY Change	29.78%	202.61%	-50.85%
Operating Profit	-$90.82M	-$162.6M	-$89.31M
YoY Change	2.89%	257.88%	-54.59%
Interest Expense	$806.0K	$790.0K	$808.0K
YoY Change	18.01%	9.42%	11.76%
% of Operating Profit
Other Income/Expense, Net	$13.17M	$27.83M	$12.41M
YoY Change	-89.12%	-4003.23%	154.18%
Pretax Income	-$77.65M	-$134.8M	-$76.90M
YoY Change	-347.34%	192.06%	-59.9%
Income Tax	-$65.00K	-$49.08M	$0.00
% Of Pretax Income
Net Earnings	-$77.58M	-$85.74M	-$76.90M
YoY Change	-337.03%	85.75%	-59.9%
Net Earnings / Revenue	-93.21%	-237.06%	-142.56%
Basic Earnings Per Share	-$0.20	-$0.25	-$0.31
Diluted Earnings Per Share	-$0.20	-$0.25	-$0.31
COMMON SHARES
Basic Shares Outstanding	380.6M shares	337.8M shares	244.4M shares
Diluted Shares Outstanding	380.8M shares	337.8M shares	244.4M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$191.4M	$284.6M	$315.0M
YoY Change	-58.52%	974.1%	437.07%
Cash & Equivalents	$191.4M	$284.6M	$315.0M
Short-Term Investments
Other Short-Term Assets	$9.698M	$7.993M	$4.096M
YoY Change	131.68%	-56.51%	-72.82%
Inventory	$44.17M	$41.60M	$36.32M
Prepaid Expenses	$17.52M	$21.55M	$17.24M
Receivables	$42.67M	$45.80M	$37.64M
Other Receivables	$1.194M	$1.110M	$125.0K
Total Short-Term Assets	$306.6M	$402.7M	$410.4M
YoY Change	-43.06%	306.72%	192.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$84.37M	$89.46M	$99.39M
YoY Change	39.84%	44.06%	53.78%
Goodwill	$181.5M	$181.2M
YoY Change
Intangibles	$190.2M	$193.7M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.968M	$7.869M	$6.953M
YoY Change	120.54%	118.83%	93.35%
Total Long-Term Assets	$522.4M	$530.6M	$107.2M
YoY Change	705.55%	593.38%	35.66%
TOTAL ASSETS
Total Short-Term Assets	$306.6M	$402.7M	$410.4M
Total Long-Term Assets	$522.4M	$530.6M	$107.2M
Total Assets	$829.0M	$933.3M	$517.7M
YoY Change	37.39%	431.68%	136.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.12M	$53.30M	$68.88M
YoY Change	-7.38%	17.84%	63.6%
Accrued Expenses	$26.15M	$23.01M	$2.458M
YoY Change
Deferred Revenue	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%	-96.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$349.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$162.3M	$204.6M	$100.6M
YoY Change	126.69%	181.77%	46.49%
LONG-TERM LIABILITIES
Long-Term Debt	$10.65M	$11.00M	$11.00M
YoY Change	-3.17%	-38.98%	-40.55%
Other Long-Term Liabilities	$20.20M	$500.0K	$500.0K
YoY Change	-6.91%	-97.72%	-97.78%
Total Long-Term Liabilities	$30.85M	$11.50M	$11.50M
YoY Change	-5.65%	-71.2%	-71.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$162.3M	$204.6M	$100.6M
Total Long-Term Liabilities	$30.85M	$11.50M	$11.50M
Total Liabilities	$267.7M	$296.0M	$188.2M
YoY Change	26.06%	-27.38%	-53.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$815.7M	-$738.1M	-$652.3M
YoY Change	52.39%	29.95%	25.01%
Common Stock	$38.00K	$38.00K	$24.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$561.3M	$637.3M	$329.4M
YoY Change
Total Liabilities & Shareholders Equity	$829.0M	$933.3M	$517.7M
YoY Change	37.39%	431.68%	136.06%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$77.58M	-$85.74M	-$76.90M
YoY Change	-337.03%	85.75%	-59.9%
Depreciation, Depletion And Amortization	$6.995M	$6.627M	$5.803M
YoY Change	27.39%	17.94%	18.38%
Cash From Operating Activities	-$88.36M	-$84.65M	-$81.49M
YoY Change	24.56%	234.55%	93.08%
INVESTING ACTIVITIES
Capital Expenditures	-$4.278M	-$3.293M	$1.378M
YoY Change	18.24%	-26.51%	-33.59%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$127.0M
YoY Change
Cash From Investing Activities	-$4.278M	-$130.3M	-$3.913M
YoY Change	18.24%	2807.77%	-21.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	-647.0K	198.1M	-$160.0K
YoY Change	-100.13%	-8460.36%	-92.98%
NET CHANGE
Cash From Operating Activities	-88.36M	-84.65M	-$81.49M
Cash From Investing Activities	-4.278M	-130.3M	-$3.913M
Cash From Financing Activities	-647.0K	198.1M	-$160.0K
Net Change In Cash	-93.29M	-16.89M	-$85.57M
YoY Change	-121.96%	-47.48%	72.93%
FREE CASH FLOW
Cash From Operating Activities	-$88.36M	-$84.65M	-$81.49M
Capital Expenditures	-$4.278M	-$3.293M	$1.378M
Free Cash Flow	-$84.08M	-$81.35M	-$82.87M
YoY Change	24.9%	290.74%	87.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Local Phone Number LocalPhoneNumber	298-6470
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Central Index Key EntityCentralIndexKey	0001818331
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39482
	dei	Entity Registrant Name EntityRegistrantName	Sema4 Holdings Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1966622
	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Ludlow Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	North Tower, 8th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
	dei	City Area Code CityAreaCode	800
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	380641510	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	284647000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45803000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26509000	usd
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1110000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	54000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	41601000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	33456000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21547000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19154000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7993000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3802000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	402701000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	483544000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44038000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89455000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	193663000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2022Q2	us-gaap	Goodwill Goodwill	181184000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14370000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7869000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6930000	usd
CY2022Q2	us-gaap	Assets Assets	933280000	usd
CY2021Q4	us-gaap	Assets Assets	554093000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	115878000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	64801000	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2354000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2623000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	473000	usd
CY2022Q2	cmlf	Lease Liabilities Current LeaseLiabilitiesCurrent	4755000	usd
CY2021Q4	cmlf	Lease Liabilities Current LeaseLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	81619000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33387000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	204606000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101284000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	usd
CY2022Q2	cmlf	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	62806000	usd
CY2021Q4	cmlf	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	500000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21907000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2668000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q2	cmlf	Warrant Liability WarrantLiability	7258000	usd
CY2021Q4	cmlf	Warrant Liability WarrantLiability	21555000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7168000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10244000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	296006000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	165990000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	379896799	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	379896799	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	380000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	242647604	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	242647604	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	38000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	24000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1375315000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	963520000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-738079000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575441000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	637274000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	933280000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	554093000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36169000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47015000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90110000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111216000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	65767000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48179000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	114083000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12870000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	116703000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	-29598000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-1164000	usd
	us-gaap	Gross Profit GrossProfit	-23973000	usd
	us-gaap	Gross Profit GrossProfit	-5487000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27168000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11952000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48483000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65085000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	36118000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18574000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	65665000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	53940000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	68034000	usd
	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	0	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	382000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	110818000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	114908000	usd
CY2022Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1731000	usd
CY2021Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	888000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	3015000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2685000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-162649000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-45448000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-251954000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-242105000	usd
CY2022Q2	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	28182000	usd
CY2021Q2	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	0	usd
	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	41372000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	409000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	790000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	722000	usd
	us-gaap	Interest Expense InterestExpense	1598000	usd
	us-gaap	Interest Expense InterestExpense	1445000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5584000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27830000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-713000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40239000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4169000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-134819000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46161000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-211715000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-237936000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-49077000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-49077000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-85742000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-46161000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-237936000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	329444000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-85742000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85742000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-85742000	usd
CY2020	cmlf	Proceeds From Government Assistance ProceedsFromGovernmentAssistance	5400000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1192000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22721000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	197659000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172000000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	637274000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162638000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-162638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162638000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1870000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40280000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	197659000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172000000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	637274000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-521826000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-46161000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1483000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-566504000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-330051000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-237936000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1483000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-566504000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-237936000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	14767000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	10521000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	40280000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	164443000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41372000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-49077000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	347000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2466000	usd
	cmlf	Noncash Lease Expense NoncashLeaseExpense	331000	usd
	cmlf	Noncash Lease Expense NoncashLeaseExpense	383000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	257000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2357000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7476000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2282000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6632000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2910000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9697000	usd
	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	-1325000	usd
	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	-295000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1126000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35712000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10028000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-473000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-442000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4807000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-7824000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-166139000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67509000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	127004000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2748000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3320000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	4458000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	6155000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134210000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9475000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	197712000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	2779000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1634000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1994000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	848000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1819000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	974000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	197897000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4647000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102452000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-81631000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118960000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299017000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37329000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1193000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1445000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	365000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q2	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1700000	usd
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	172000000	usd
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3243000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	87000	usd
	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1118000	usd
	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1225000	usd
	cmlf	Deferred Transaction Costs Incurred But Not Yet Paid DeferredTransactionCostsIncurredButNotYetPaid	53000	usd
	cmlf	Deferred Transaction Costs Incurred But Not Yet Paid DeferredTransactionCostsIncurredButNotYetPaid	5799000	usd
	cmlf	Non Cash Impact Of Shares Reclassified NonCashImpactOfSharesReclassified	0	usd
	cmlf	Non Cash Impact Of Shares Reclassified NonCashImpactOfSharesReclassified	1483000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sema4 Holdings Corp. (“Sema4 Holdings”) through its subsidiaries Sema4 OpCo, Inc., formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”), and GeneDx Holding 2, LLC, provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. Legacy Sema4 primarily serves healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Business Combination Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Business Combination Merger” and, together with the other transactions contemplated by the Business Combination Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Business Combination Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Business Combination Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock (the “Class A common stock”) (the “Conversion Ratio”).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Business Combination Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 29, 2022, the Company consummated the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 14, 2022 (as amended, the “ Acquisition Merger Agreement”), by and among the Company and GeneDx, Inc. (“GeneDx”), a New Jersey corporation and wholly-owned subsidiary of OPKO Health, Inc. (“OPKO”), GeneDx Holding 2, Inc., which held 100% of GeneDx (“Holdco2”), at the Effective Time (as defined in the Acquisition Merger Agreement) and OPKO, which provided for, among other things, the acquisition of GeneDx from OPKO. After giving effect to the mergers and the other transactions contemplated by the Acquisition Merger Agreement (the “Acquisition”), GeneDx was converted into a Delaware limited liability company and became the Company’s wholly-owned indirect subsidiary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, “Business Combination,” for additional details regarding the Business Combination and Acquisition.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiaries following the consummation of the Business Combination.</span></div>
CY2020Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	3800000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liabilities and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of June 30, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that </span></div>accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.
CY2021Q4	cmlf	Payment Of Deferred Payroll Taxes PaymentOfDeferredPayrollTaxes	1900000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	500000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	284647000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14370000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299017000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21995000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21994972	shares
CY2021Q4	cmlf	Warrants To Purchase Public Warrants WarrantsToPurchasePublicWarrants	14758305	shares
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	cmlf	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	18.00
	cmlf	Redemption Price Per Warrant RedemptionPricePerWarrant	0.01
	cmlf	Number Of Days For Written Notice Of Redemption NumberOfDaysForWrittenNoticeOfRedemption	30	d
	cmlf	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	d
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14025000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14025000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	196000000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	193663000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	7012000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14025000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	14025000	usd
CY2022Q2	cmlf	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	130551000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	193663000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111216000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	30100000	usd
CY2022Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	48293000	usd
CY2021Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	76653000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	138370000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	163665000	usd
CY2022Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-147732000	usd
CY2021Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-54346000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-243636000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-308703000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36169000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47015000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90110000	usd
CY2021	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	24200000	usd
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9000000	usd
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3296000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3769000	usd
	cmlf	Contract With Customer Asset Additions ContractWithCustomerAssetAdditions	1067000	usd
	cmlf	Contract With Customer Liability Prepayments ContractWithCustomerLiabilityPrepayments	350000	usd
	cmlf	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	945000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4363000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3174000	usd
CY2021Q2	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1400000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	usd
CY2022Q2	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	200000	usd
CY2021Q2	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	1500000	usd
	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	700000	usd
	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	2200000	usd
CY2022Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	800000	usd
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1800000	usd
CY2022Q2	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	700000	usd
CY2021Q2	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	300000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1000000.0	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	500000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	284600000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	3300000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2600000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3400000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10200000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3300000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-10100000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	153791000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	114625000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64336000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51906000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89455000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6600000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5600000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12400000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10500000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6627000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5619000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12430000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10521000	usd
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0400
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	875000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2131000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2174000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2218000	usd
CY2022Q2	cmlf	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	3602000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	11000000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	usd
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	900000	usd
CY2022Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	900000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P9Y
CY2022Q2	cmlf	Lessee Finance Lease Interest Rate LesseeFinanceLeaseInterestRate	0.131
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3400000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18400000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44038000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	12160000	usd
CY2022Q2	cmlf	Lease Assets LeaseAssets	56198000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45484000	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	17322000	usd
CY2022Q2	cmlf	Lease Liabilities LeaseLiabilities	68431000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1582000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2962000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	137000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	306000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	152000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	279000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1871000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	3547000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	912000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	51800000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1824000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	531000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1083000	usd
CY2022Q2	cmlf	Finance Lease Costs FinanceLeaseCosts	1443000	usd
	cmlf	Finance Lease Costs FinanceLeaseCosts	2907000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	3314000	usd
	us-gaap	Lease Cost LeaseCost	6454000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2684000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	2532000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Remainder Of Fiscal Year LesseeOperatingAndFinanceAndLiabilityToBePaidRemainderOfFiscalYear	5216000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3994000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3584000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Year One LesseeOperatingAndFinanceAndLiabilityToBePaidYearOne	7578000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5504000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2763000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Two LesseeOperatingAndFinanceAndLiabilityToBePaidYearTwo	8267000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5925000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2451000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Three LesseeOperatingAndFinanceAndLiabilityToBePaidYearThree	8376000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6066000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2003000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Four LesseeOperatingAndFinanceAndLiabilityToBePaidYearFour	8069000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	57511000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	49884000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Five LesseeOperatingAndFinanceAndLiabilityToBePaidYearFive	107395000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	81684000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	63217000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability To Be Paid LesseeOperatingAndFinanceAndLiabilityToBePaid	144901000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33819000	usd
CY2022Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	42651000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability Undiscounted Excess Amount LesseeOperatingAndFinanceAndLiabilityUndiscountedExcessAmount	76470000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	47865000	usd
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	20566000	usd
CY2022Q2	cmlf	Lessee Operating And Finance And Liability LesseeOperatingAndFinanceAndLiability	68431000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y8M12D
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P18Y2M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.107
	us-gaap	Operating Lease Payments OperatingLeasePayments	2644000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1083000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1634000	usd
	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	consultant
CY2022Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	28400000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	2.20
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	2100000	usd
	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	employee
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22721000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-519000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40280000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164443000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-49100000	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0027
CY2022Q2	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-48600000	usd
CY2022Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-48600000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-85742000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85742000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-46161000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	337752029	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	337752029	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1100734	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1100734	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-41.94
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-41.94
	us-gaap	Net Income Loss NetIncomeLoss	-162638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-237936000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	291318351	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	291318351	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	826778	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	826778	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-287.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-287.79
	cmlf	Conversion Ratio ConversionRatio	123.8339
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	97861016	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200438393	shares
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	9561000	usd
	us-gaap	Payments For Restructuring PaymentsForRestructuring	6357000	usd
CY2022Q2	us-gaap	Restructuring Reserve RestructuringReserve	3204000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	53302000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	44693000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23007000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19758000	usd
CY2022Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	39194000	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	0	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	375000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	350000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	115878000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	64801000	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12353000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	13561000	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10883000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7013000	usd
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3106000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1057000	usd
CY2022Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2881000	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2826000	usd
CY2022Q2	cmlf	Indemnification Liabilities Current IndemnificationLiabilitiesCurrent	13470000	usd
CY2021Q4	cmlf	Indemnification Liabilities Current IndemnificationLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	28000000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2022Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	10926000	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	8930000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	81619000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33387000	usd

Files In Submission

Name	View Source	Status
0001818331-22-000069-index-headers.html	Edgar Link	pending
0001818331-22-000069-index.html	Edgar Link	pending
0001818331-22-000069.txt	Edgar Link	pending
0001818331-22-000069-xbrl.zip	Edgar Link	pending
ceocertificationfor-ex311x.htm	Edgar Link	pending
ceocertificationfor-ex321x.htm	Edgar Link	pending
cfocertificationfor-ex312x.htm	Edgar Link	pending
cfocertificationfor-ex322x.htm	Edgar Link	pending
cmlf-20220630.htm	Edgar Link	pending
cmlf-20220630.xsd	Edgar Link	pending
cmlf-20220630_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
cmlf-20220630_pre.xml	Edgar Link	unprocessable
cmlf-20220630_cal.xml	Edgar Link	unprocessable
cmlf-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cmlf-20220630_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sema4-agreementeschadt.htm	Edgar Link	pending
sema4-iroconsultingagreeme.htm	Edgar Link	pending
Show.js	Edgar Link	pending
cmlf-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WGS
GeneDx Holdings Corp. Stock $wgs

2022 Q3 Form 10-Q Financial Statement

#000181833122000069 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS GeneDx Holdings Corp. Stock $wgs

2022 Q3 Form 10-Q Financial Statement

#000181833122000069 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS
GeneDx Holdings Corp. Stock $wgs